(Date:10/10/2008)...ick Teams Up with Legal and Medical Panel to Offer...Careers Seminar in,Knoxville, KNOXVILLE, Tenn., O...Breast Cancer Awareness Month, Cancer and Careers ...with YWCA Knoxville, The Wellness Community-East,T... University of Tennessee,women,s basketball associ...
(Date:10/10/2008)... The Healthcare Technology Evolution: Smarter... Exton, PA (PRWEB) September 17, 2008 -...he national Healthcare Information Management Syst...regional health information technology professiona...tled The Healthcare Technology Evolution: Smarter ...
(Date:10/10/2008)...edical Center (BMC) has received a $5,807,469 gran...ging (NIA) to fund the Boston Claude D. Pepper Old...ter is one of only 11 Pepper Centers in the countr...endence Center Program was established in honor of...ida. During his five decades of public service, Pe...
(Date:10/10/2008)... metabolic information from PET to traditional CT ...for maximized workflow efficiency an...t. 10 /PRNewswire/ -- Siemens Healthcare, (http://...CT, a new concept in,integrated imaging that provi... solution for today,s shrinking healthcare budget....
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4...merican Association for Cancer Research has leaned...ing skin with broccoli and garlic after several st...tues of the same.// After being [resented with ir...e view that the best way of prolonging your life m...
...gues have found a new cheek cell analysis which de...nd a simple, inexpensive and early screening metho...gh risk for cancer using buccal mucosa or cells sc...contain information that separates patients with l...
...ection methods use heart activity, but now the sto... for lie detection reports the online edition of N...richa at the University of Texas found that the he...ot only by the brain but also by factors such as h...
...ee of polio. Only 30 cases have been reported till...ase by government of India.// In the whole of 2...ily Welfare Minister, Dr. Anbumani Ramadoss is exp...end of this year or early next year that India is ...
Other Medicine News:Health News:Early Lung cancer detected by studying Cheek Cells 2(Date:10/8/2008)...eview Zanolimumab Program to be Discontinued and H...the Results of its Portfolio Review; Zanolimumab ...duce the Number of E...Call/ -- Genmab A/S (OMX: GEN),announced today tha...HuMax-CD4(R)). In addition, as a result of a portf...
(Date:10/8/2008)... LYON, France, Oct. 8 /- Vical Incor...ded clinical data and new nonclinical data,demonst...y be broadly,applicable in DNA- and protein-based ...er vaccines. Alain P. Rolland, Pharm.D., Ph.D., Vi..., will present the data today,Wednesday, October ...
(Date:10/7/2008)...udy evaluates the efficacy of new device for detec...ed during colonoscopy, ORLANDO, Fla., Oct. 7 /PRN...ology Annual Scientific Meeting in Orlando (ACG 20...D presented results from a,multi-institutional cli...rd,Eye(R) Retroscope(R), a new device that is desi...
(Date:10/7/2008)...Study Showed Larazotide Acetate Prevented Immunolo...atients with Celiac Disease, Additional Data Indic...ase, ORLANDO, Fla., Oct. 7 /- Alba T... clinical studies this week at the American,Colleg... Meeting. Data from,study CLIN 1001-004, the first...
Breaking Medicine Technology:Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies 2143 1Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies 2143 2Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies 2143 3Teen Blood Donors More Prone to Complications 19928 1Teen Blood Donors More Prone to Complications 19928 2Teen Blood Donors More Prone to Complications 19928 3Invasive methods unnecessary for prostate cancer radiation therapy treatment planning 19925 1Invasive methods unnecessary for prostate cancer radiation therapy treatment planning 19925 2Ambulatory Services of America Inc Announces Joint Venture With Denton Cancer Center LP 19922 1Ambulatory Services of America Inc Announces Joint Venture With Denton Cancer Center LP 19922 2...Journal of Clinical Oncology -, NEW YORK, July 06,...se II study - which will be published in the Augus...gy (JCO) and are now,available as an Early Release...co.org/">www.jco.org - demonstrate that,ixabepilo...,compound, has activity in patients with metastati...
...25, an Investigational NNRTI,from Tibotec, YARDLEY...,ongoing Phase 3 studies (DUET-1 and DUET-2) showe...umented non-nucleoside reverse,transcriptase inhib...e reached an undetectable viral load (defined as a...NA copies/mL) with,TMC125 (etravirine), Tibotec,s ...
Other Medicine Technology:Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 2Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 3Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 4TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4...veloped a range of Milli-Q ultrapure water systems...ents. Each of the five new Milli-Q systems is desi...al to particular applications such as HPLC, molecu...high precision resistivity monitor that records co...
...veloped a range of Milli-Q ultrapure water systems...ents. Each of the five new Milli-Q systems is desi...al to particular applications such as HPLC, molecu...high precision resistivity monitor that records co...
Inquire
Adjustable speed vortex with inter-changeable heads, 110 V
Medicine Products: